Bodyport Raises $11.2M in Series A Funding
Bodyport, a San Francisco, CA-based digital health company focused on the detection and management of heart disease, closed an $11.2m Series A funding round. The round, which brings total funding to $15.8m, was led by Boehringer Ingelheim Venture Fund with participation from existing investors Playground Global and Initialized Capital, among others. Boehringer Ingelheim Venture Fund’s Dr. Debbie Lin, Playground Global’s Bruce Leak, and Initialized Capital’s Garry Tan will join the board of directors. Rather than relying on wearables, the Bodyport Scale is designed to detect cardiac signals and biomarkers through a user’s feet, powering algorithms that have the potential to predict risk and enable optimized, early interventions. The company is initially focused on improving the management of heart failure.